Hypertension Diagnostics Valuation
| HDIIDelisted Stock | USD 0 0.0008 38.10% |
Hypertension Diagnostics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Hypertension Diagnostics from evaluating the firm fundamentals such as Profit Margin of (0.03) %, return on asset of 3.0E-4, and Shares Outstanding of 52.39 M as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Hypertension Diagnostics' price fluctuation is very steady at this time. Calculation of the real value of Hypertension Diagnostics is based on 3 months time horizon. Increasing Hypertension Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Hypertension Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hypertension Pink Sheet. However, Hypertension Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0029 | Real 0.002768 | Hype 0.003625 |
The intrinsic value of Hypertension Diagnostics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Hypertension Diagnostics' stock price.
Estimating the potential upside or downside of Hypertension Diagnostics helps investors to forecast how Hypertension pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hypertension Diagnostics more accurately as focusing exclusively on Hypertension Diagnostics' fundamentals will not take into account other important factors: Hypertension Diagnostics Total Value Analysis
Hypertension Diagnostics is currently forecasted to have valuation of 5.26 M with market capitalization of 730.42 K, debt of 4.69 M, and cash on hands of 5.66 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Hypertension Diagnostics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.26 M | 730.42 K | 4.69 M | 5.66 K |
Hypertension Diagnostics Investor Information
The company recorded a loss per share of 0.0. Hypertension Diagnostics had not issued any dividends in recent years. Based on the key indicators related to Hypertension Diagnostics' liquidity, profitability, solvency, and operating efficiency, Hypertension Diagnostics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Hypertension Diagnostics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Hypertension signifies not a very effective usage of assets in November.Hypertension Diagnostics Profitability Analysis
The company reported the previous year's revenue of 3.79 M. Net Loss for the year was (125.39 K) with profit before overhead, payroll, taxes, and interest of 954.47 K.About Hypertension Diagnostics Valuation
An absolute valuation paradigm, as applied to Hypertension Pink Sheet, attempts to find the value of Hypertension Diagnostics based on its fundamental and basic technical indicators. By analyzing Hypertension Diagnostics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Hypertension Diagnostics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Hypertension Diagnostics. We calculate exposure to Hypertension Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Hypertension Diagnostics's related companies.Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Hypertension Diagnostics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Hypertension Diagnostics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Hypertension Diagnostics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Hypertension Diagnostics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Hypertension Diagnostics' revenue streams: Identify Hypertension Diagnostics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Hypertension Diagnostics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Hypertension Diagnostics' growth potential: Evaluate Hypertension Diagnostics' management, business model, and growth potential.
- Determine Hypertension Diagnostics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Hypertension Diagnostics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Hypertension Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 52.4 M | |
| Retained Earnings | -33.7 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance |